A Single-Arm Study Evaluating Carboplatin/Gemcitabine in Combination With BSI-201 in Patients With Platinum-Sensitive Recurrent Ovarian Cancer
NCT01033123
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
41
Enrollment
INDUSTRY
Sponsor class
Conditions
Ovarian Cancer
Interventions
DRUG:
BSI-201
Sponsor
Sanofi